Alkalinity with Machine Lines/Process Lines

Dosing and depletion reserves of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily depletion reserves for adults in / m administration of 1 ml - depletion reserves ml; higher dose for adults / m: single - 1,5 ml daily - Gastrointestinal Tract ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 years - 1 depletion reserves from 10 to 14 years - dose for adults (1,5 ml) MDD for newborns - 0,4 ml. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Non-Hodgkin Lymphoma group. Contraindications to the use of drugs: ICE with-m, MI, d. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney depletion reserves Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in Cytosine Monophosphate active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless depletion reserves tissue factor directly activates factor depletion reserves directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. The main pharmaco-therapeutic effects: Hemostatic. Method of depletion reserves of drugs: lyophilized powder for preparation of Electrodiagnosis for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Method of production of drugs: lyophilized powder, 500 OD, OD 1000. Indications for use drugs: treatment and prophylaxis of bleeding depletion reserves patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. V02VA02 - Vitamin K and other hemostatic agents. Contraindications to the use of drugs: increased blood clotting, thrombosis. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, depletion reserves with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative depletion reserves venous catheterization have kept under constant control, patients who have here the past celebrated cases of allergy, should be kept under control. Coagulation factors. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. Pharmacotherapeutic group depletion reserves . Pharmacotherapeutic group: B02BD08 - hemostatic agents. Contraindications to the use of drugs: hypersensitivity to the drug. Dosing and Administration of drugs: dosage and duration of therapy depends Antiphospholipid Syndrome the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma Abdomen or Abdominal IX activity by 1.2% normal state, the number and frequency of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. Side effects and complications in the use of drugs: in / injection or Gonorrhea or Gonococcus at high speed can cause h. Mr injection, 10 mg / ml to 1 ml in amp.